MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

Cycloheximide

CAS No. : 66-81-9

MCE 站：Cycloheximide

产品活性：Cycloheximide (Naramycin A) 是一种抗真菌 (antifungal) 抗生素，是真核生物蛋白质合成 (protein synthesis) 的抑制剂，抑制体内蛋白质合成和 RNA 合成的 IC₅₀ 值分别为 532.5 nM 和 2880 nM。Cycloheximide 可抑制铁死亡 (ferroptosis) 并抑制自噬 (autophagy)。

研究领域：Cell Cycle/DNA Damage  |  Anti-infection  |  Autophagy  |  Apoptosis

作用靶点：DNA/RNA Synthesis  |  Fungal  |  Autophagy  |  Ferroptosis  |  Antibiotic

In Vitro: Cycloheximide (CHX) is the most common laboratory reagent used to inhibit protein synthesis. Cycloheximide has been shown to block the elongation phase of eukaryotic translation. Cycloheximide binds the ribosome and inhibits eEF2-mediated translocation. Surprisingly, Cycloheximide allows one complete translocation cycle to proceed before halting any further elongation. Cycloheximide has been speculated that Cycloheximide requires an E-site bound deacylated tRNA for activity.

In Vivo: The mice receive Cycloheximide injections at 30, 60, or 120 mg/kg prior to training with a 200 ?A shock. There is a significant effect of Cycloheximide on latencies on the memory test trials (P<0.001). In saline controls, this shock level results in latencies on the test trial that are significantly higher than those at training. Injections of the lowest dose of Cycloheximide tested, 30 mg/kg, results in latencies on the test trial that are significantly higher than those seen in the saline control group. Mice receiving either of the two higher doses of Cycloheximide has latencies on the test trial that are comparable to those of the saline group, i.e., the higher doses neither enhanced nor impaired memory under these conditions, resulting in an inverted-U dose-response curve for Cycloheximide enhancement of memory. Infarct volume, as measured by morphometric analysis of infarct areas with triphenyl tetrazolium chloride (TTC), is significantly reduced by 92% and 61% when Cycloheximide is given 0 or 6 hr after HI respectively, but shows an insignificant trend in infarct reduction if Cycloheximide is administered 12 hr after hypoxia-ischemia (HI) compared to the HI control group, and no protective effect is observed when administration is delayed until 24 hr after HI.

相关产品：Apoptosis Compound Library  |  Anti-Infection Compound Library  |  Anti-Fungal Compound Library  |  Natural Product Library Plus  |  Anti-Aging Compound Library  |  Natural Product Library  |  Ferroptosis Compound Library  |  Anti-Cancer Compound Library  |  Antibiotics Library  |  Cell Cycle/DNA Damage Compound Library  |  Bioactive Compound Library Plus  |  Autophagy Compound Library  |  Rapamycin  |  Actinomycin D  |  Cisplatin  |  Mitomycin C  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Chloroquine phosphate  |  Erastin  |  Puromycin dihydrochloride  |  SP600125  |  Sorafenib  |  Ferrostatin-1  |  Staurosporine  |  Gemcitabine  |  Remdesivir  |  Acetylcysteine  |  Deferoxamine mesylate  |  Dexamethasone  |  ML385  |  Necrostatin-1  |  Etoposide  |  Tunicamycin  |  5-Azacytidine  |  Doxycycline (hyclate)  |  Brefeldin A  |  Nigericin sodium salt  |  G-418 disulfate  |  RSL3  |  SB 202190  |  Bleomycin sulfate

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。